Want to see CGON full AI Analyst Report?
CG Oncology, Inc. (CGON) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cretostimogene Grenadenorepvec | High-Risk Non-Muscle-Invasive Bladder Cancer | Phase II | Recruiting | Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Aug 14, 2024 | ― |
| Cretostimogene Grenadenorepvec, N-Dodecyl-B-D-Maltoside | Bladder Cancer, Urothelial Carcinoma, Non Muscle Invasive Bladder Cancer, Urologic Cancer | Phase III | Active Not Recruiting | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | Oct 25, 2023 | ― |
| Cretostimogene Grenadenorepvec, N-Dodecyl-B-D-Maltoside | Non Muscle Invasive Bladder Cancer, High-Grade Ta/ T1 Papillary Disease Bladder Cancer | Phase III | Active Not Recruiting | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin | Jun 26, 2020 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cretostimogene Grenadenorepvec | Phase II | High-Risk Non-Muscle-Invasive Bladder Cancer | Recruiting | Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Aug 14, 2024 | ― |
| Cretostimogene Grenadenorepvec, N-Dodecyl-B-D-Maltoside | Phase III | Bladder Cancer, Urothelial Carcinoma, Non Muscle Invasive Bladder Cancer, Urologic Cancer | Active Not Recruiting | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | Oct 25, 2023 | ― |
| Cretostimogene Grenadenorepvec, N-Dodecyl-B-D-Maltoside | Phase III | Non Muscle Invasive Bladder Cancer, High-Grade Ta/ T1 Papillary Disease Bladder Cancer | Active Not Recruiting | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin | Jun 26, 2020 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does CG Oncology, Inc. (CGON) have in its pipeline
CG Oncology, Inc. CGON is currently developing the following drugs: Cretostimogene Grenadenorepvec, Cretostimogene Grenadenorepvec, N-Dodecyl-B-D-Maltoside. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
